title: Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.
abstract: We retrospectively analyzed 194 previously untreated acute myeloid leukemia (AML) patients to evaluate the role of Day 14 bone marrow (BM) biopsy in predicting complete remission (CR). Sixty-seven percent received induction therapy. Achieving Day 14 BM < or =5% blasts was strongly predictive of Day 28 CR with 90% sensitivity and 79% positive predictive value; but weak 43% specificity and 29% negative predictive value. Day 14 BM biopsy is highly sensitive in predicting CR, but did not predict overall survival. Some patients with BM blast >5% at Day 14 may still achieve a Day 28 CR, and not necessarily need reinduction therapy though high risk cytochemical or cytogenetic phenotype predicts a need for retreatment.
authors.affiliation: Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA.
authors.forename: Kebede
authors.initials: K
authors.lastname: Hussein
authors.forename: Balkrishna
authors.initials: B
authors.lastname: Jahagirdar
authors.forename: Pankaj
authors.initials: P
authors.lastname: Gupta
authors.forename: Linda
authors.initials: L
authors.lastname: Burns
authors.forename: Karen
authors.initials: K
authors.lastname: Larsen
authors.forename: Daniel
authors.initials: D
authors.lastname: Weisdorf
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001752:Blast Crisis / Q000175:diagnosis / Q000473:pathology*; D001856:Bone Marrow Examination; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors